Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Lviv,,Ukraine,-,February,13,,2025:,Circular,Logo,Sign,Featuring

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIRO

APVO

CAPR

DGNX

HSHP

MESO

SWBI

Smith &amp; Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Munich,,Bavaria,,Germany,-,March,31,2023:,Cheetah,Mobile,Provides

ARQQ

BBGI

BIYA

CLRB

CMBM

CMCM

DFLI

GOVX

NWGL

OSCR

PCSA

PTLE

WHLR

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

Washington,,Dc,-,April,21,,2019:,Booz,Allen,Hamilton,-

BWMX

CMRE

INNV

MAZE

NEXA

SLSR

Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

Press Releases

General

Ryoncil® is Now Available for Purchase in the United States

Health Care

First Three Children to Commence Treatment With Ryoncil®

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Politics

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Management

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Earnings

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

ADIA

CRSP

FATE

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

Beam Therapeutics

Biohaven

CareDx

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MannKind

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Piper Sandler

Maxim Group

Chardan Capital

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

BCLI

BRTX

LGVN

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Comments

Mesoblast

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell